Verapamil reduced attack frequency and the use of abortive agents in episodic cluster headache


Question
What is the effectiveness of verapamil as a prophylaxis for episodic cluster headache?

Design
Randomized [allocation concealed*],† blinded [clinicians, patients, and outcome assessors*],† placebo-controlled trial with 2-week follow-up.

Setting
3 outpatient clinics in Italy.

Patients
30 adults between 18 and 60 years of age (mean age 44 y, 90% men) who were outpatients and had a diagnosis of episodic cluster headache (International Headache Society criteria) with ≥ 1 previous cluster period lasting ≥ 1 month and who had been in a cluster period for ≤ 10 days and had an expected duration of the remainder of the cluster period of ≥ 20 days. Exclusion criteria were liver or kidney disease, cardiopathologic findings contraindicating verapamil use, psychiatric disorder, use of antidepressants or antipsychotics, drug or alcohol abuse, or previous adynamic ileus. Follow-up was 100%.

Intervention
After a 5-day run-in period, patients were allocated to verapamil, 120 mg 3 times/d (n = 15), or placebo, 3 times/d (n = 15), for 2 weeks.

Main Outcome Measures
Self-reported frequency of cluster headache attacks and use of abortive agents.

Main Results
During the first week of treatment, the verapamil and placebo groups did not differ for median numbers of attacks/d (1.1 vs 1.7) or abortive agents used/d (1.0 vs 1.2). During the second week of treatment, verapamil was more effective than placebo in reducing both the number of attacks (median 0.6 vs 1.65/d, P < 0.001) and the number of abortive agents used (median 0.5 vs 1.2/d, P < 0.004). Fewer patients in the verapamil group than in the placebo group were nonresponders (i.e., having a ≤ 50% reduction in attack frequency) [P < 0.001‡ (Table). Side effects experienced during the treatment period were mild.

Conclusion
Verapamil reduced attack frequency and the use of abortive agents in patients with episodic cluster headache.

Source of funding: No external funding.

For correspondence: Dr. G. Bussone, Istituto Nazionale Neurologico Carlo Besta, via Celoria 11, 20133 Milan, Italy. FAX 39-02-7063-8067.

*See Glossary.
†Information provided by author.
‡ P value calculated from data in article.

Verapamil vs placebo for prophylactic treatment of episodic cluster headache at 2 weeks§

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Verapamil</th>
<th>Placebo</th>
<th>RRR (95% CI)</th>
<th>NNT (CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nonresponse¶</td>
<td>20%</td>
<td>100%</td>
<td>80% (53 to 93)</td>
<td>1 (1 to 2)</td>
</tr>
</tbody>
</table>

§Abbreviations defined in Glossary; RRR, NNT, and CI calculated from data in article.
¶Nonresponse = having a ≤ 50% reduction in attack frequency.

Commentary
Treatment of cluster headache includes aborting any current headache and prophylaxis to prevent headaches both during the current cluster and in future clusters. Of the drugs used for prophylactic treatment, prednisone is the most studied. 1 blinded, crossover study and several unblinded studies showed that prednisone completely stopped cluster headaches in 60% (1) to 90% (2) of patients.

This randomized controlled trial by Leone and colleagues adds to the sparse literature on prophylaxis of cluster headaches. As with many studies of cluster headaches, this study used a small sample size and had a short follow-up duration, but it appears to have valid results.

The study confirms that verapamil is an effective alternative for the prophylaxis of cluster headaches. In the absence of a direct comparison between verapamil and prednisone, verapamil is the first choice for patients requiring frequent prophylaxis. The choice for infrequent prophylaxis should depend on a patient’s previous experience and potential for drug-related adverse effects. We now need a study with a factorial design that compares verapamil, prednisone, and their combination.

A previous study showed that verapamil is more effective than lithium and has fewer side effects (3). Although methysergide is commonly prescribed, no controlled trials have compared this drug with placebo or verapamil.

Robert Badgett, MD
University of Texas Health Sciences Center
San Antonio, Texas, USA

References